Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-28Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; currently active-not-recruiting.
-
CLINICAL_TRIALS trial_result · 2026-07-31Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial exploring pembrolizumab as adjuvant therapy for triple-negative breast cancer is actively not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating pembrolizumab as adjuvant therapy for triple-negative breast cancer is active/not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours [Phase 1, Phase 2]
Phase 1/2 trial results of NUC-3373 in combination with other agents in patients with advanced solid tumors; study status terminated with re…
-
CLINICAL_TRIALS trial_result · 2026-07-21Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 clinical trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; status ACTIVE_NOT_RECRUITIN…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Results: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer [EARLY_Phase 1]
Early-phase trial results of adjuvant alpha-lactalbumin vaccine in triple-negative breast cancer were completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2026-07-13Clinical Trial Results: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]
Phase 1/2 trial results for TC-510 in advanced mesothelin-expressing cancers were terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2026-07-07Clinical Trial Results: Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations [Phase 2]
Phase 2 trial evaluating nab-paclitaxel in combination with alpelisib for anthracycline-refractory triple-negative breast cancer with PIK3CA…
-
CLINICAL_TRIALS trial_result · 2026-07-02Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 clinical trial update for pembrolizumab as adjuvant therapy in triple-negative breast cancer, status ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2026-07-01Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer is ongoing with active status.
-
CLINICAL_TRIALS trial_result · 2026-06-17Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial updating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; study status ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial investigating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; currently active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers [Phase 1]
A Phase I trial evaluating [177Lu]Lu-NNS309, a radiopharmaceutical, in multiple advanced cancers including pancreatic ductal adenocarcinoma,…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
A real-world, patient-reported outcome study of Sacituzumab Govitecan in Chinese patients with metastatic triple-negative breast cancer; the…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating atezolizumab plus capecitabine as adjuvant therapy for triple-negative breast cancer, reporting on efficacy and saf…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation [Phase 2]
Phase 2 clinical trial update for ASTRAEA investigating a combination of myeloid inhibition and radiation in metastatic triple-negative brea…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies [Phase 1]
Phase 1 clinical trial evaluating CTX-8371 in patients with advanced malignancies, including Non-Small Cell Lung Cancer and Triple-Negative …
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer [Phase 2]
A Phase 2 study is evaluating SDX-7320 with Eribulin for breast cancer, including metastatic triple-negative breast cancer. The trial is cur…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment [Phase 3]
Phase 3 clinical trial evaluating toripalimab in combination with nab-paclitaxel for metastatic or recurrent triple-negative breast cancer h…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) [Phase 1, Phase 2]
MD Anderson is running a Phase 1/2 trial to evaluate the combination of Naxitamab and Sacituzumab Govitecan in metastatic triple-negative br…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer [Phase 1]
Phase 1 trial testing the combination of ZEN003694 and Binimetinib in patients with advanced, metastatic, or unresectable solid tumors with …
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases [Phase 2]
Phase 2 trial evaluating cisplatin with or without veliparib in patients with recurrent or metastatic triple-negative or BRCA mutation-assoc…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer [Phase 2]
Phase 2 neoadjuvant trial evaluating pembrolizumab with carboplatin and paclitaxel for Stage I triple-negative breast cancer is currently ac…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC [Phase 2]
This report covers a Phase 2 clinical trial evaluating the efficacy and safety of combining sintilimab, anlotinib, and chemotherapy as neoad…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer [Phase 2]
Phase II trial evaluating Ivonescimab with carboplatin and docetaxel in early-stage triple-negative breast cancer is currently recruiting. T…